Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan + Retlirafusp Alfa ± Pertuzumab in Neoadjuvant HER2+ Gastric/GEJ Adenocarcinoma
NCT07716111Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, retlirafusp alfa, pertuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanretlirafusp alfapertuzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07716111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07716111.